Position in NVS
as of Jun 30, 2026
· filed Jul 31, 2026
Position Value
$521,249
+$13,204 QoQ
Shares Held
3,326
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.40%
of 13F equity value
Holder Rank
#868
of 1,603 holders
Holding Since
Mar 2020
9 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Axiom Investment Management LLC holds $9,628,805 across 10 Drug Manufacturers - General names. NVS ranks #8 (5.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PFE |
Pfizer Inc
|
86,053 | $2,072,142 | |
| 2 | LLY |
ELI LILLY & Co
|
1,400 | $1,679,191 | |
| 3 | BMY |
Bristol Myers Squibb Co
|
23,292 | $1,342,081 | |
| 4 | ABBV |
AbbVie Inc.
|
4,806 | $1,209,381 | |
| 5 | JNJ |
Johnson & Johnson
|
3,978 | $1,010,288 | |
| 6 | MRK |
Merck & Co., Inc.
|
6,417 | $824,580 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
6,343 | $801,374 | |
| 8 | NVS |
Novartis AG
This page
|
3,326 | $521,249 |
All Filings in NVS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $521,249 | 3,326 | Shares | Sole | 2026-07-31 | |
| 2026-03-31 | $508,045 | 3,326 | Shares | Sole | 2026-05-26 | |
| 2022-09-30 | $6,080 | 80 | Shares | Sole | 2022-11-14 | |
| 2021-09-30 | $231,185 | 2,827 | Shares | Sole | 2021-10-18 | |
| 2021-06-30 | $326,358 | 3,577 | Shares | Sole | 2021-08-16 | |
| 2020-12-31 | $134,140 | 1,504 | Shares | Sole | 2021-02-11 | |
| 2020-09-30 | $481,920 | 5,542 | Shares | Sole | 2021-03-16 | |
| 2020-06-30 | $484,028 | 5,542 | Shares | Sole | 2021-03-16 | |
| 2020-03-31 | $530,800 | 6,438 | Shares | Sole | 2021-03-16 | |
| No filing history on record for this holder in this stock. | ||||||